Machín GSA, Rubio BY, González OA, Menéndez VA, Gil AM, Valdés CF

Language: Spanish
References: 21
Page: 1-11
PDF size: 206.31 Kb.

ABSTRACT

L-asparaginase is a medication used in different phases of all current treatment protocols for acute lymphoid leukemia. Multiple secondary manifestations to L- asparaginase are described, and allergic reactions are the most frequent. We studied 144 children with acute lymphoblastic leukemia treated at the Instituto de Hematología e Inmunología between 1998 and 2013. Thirty patients (21%) had allergic reactions, similar to what is described in literature; 76.6% of them had received a cumulative dose of less than 80 000 IU (average of 48 757); and the highest number of allergic reactions (86.7%) was reported between doses 9 and 18 received (mean of 11 doses). A greater global survival was observed in patients who received more doses (19 - 26 doses) (p=0.003). Event free survival was also higher in this group (p= 0.357).

REFERENCES

1. Larson RA. Acute Lymphoblastic Leukemia In: Kaushansky K, Prchal JT, Press OW, Lichtman MA, Levi M, Burns LJ, et al. Williams Hematology. 9th ed. New York: McGraw-Hill Education;2016. p. 1505. [ Links ]

2. Snodgrass R, Nguyen LT, Guo M, Vaska M, Naugler C, Rashid-Kolvear F. Incidence of acute lymphocytic leukemia in Calgary, Alberta, Canada: a retrospective cohort study. BMC Res Notes. 2018 Feb 7;11(1):104. doi: 10.1186/s13104-018-3225-9. [ Links ]

3. Tai EW, Ward KC, Bonaventure A, Siegel DA, Coleman MP. Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study. Cancer. 2017 Dec;123(Suppl 24):5178-89. [ Links ]

4. Santiago R, Vairy S, Sinnett D, Krajinovic M, Bittencourt H. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother. 2017 Aug;18(11):1081-99. [ Links ]

5. Gutiérrez A, Silverman LB. Acute Lymphoblastic Leukemia In: Nathan and Oski(s. Hematology and Oncology of Infancy and Childhood. 8th ed. Philadelphia: El SERVIER Saunders;2015. p. 1527. [ Links ]

6. Marsán Suárez V, del Valle Pérez LO, Díaz Domínguez G, Macías Abraham C, Machin García S, Lam Díaz RM, et al. Correlación entre morfología y citometría de flujo en la Leucemia Linfoide Aguda infantil. Rev Cubana Hemato Inmuno Hemoter [revista en Internet]. 2016 [citado:04/02/2018];32(4):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/445 [ Links ]

7. Chiaretti S, Gianfelici V, Brien SM, Mullighan CG. Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2016;35:e314-22. [ Links ]

8. Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 1967 Dec;27(12):2619-31. [ Links ]

9. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA. 1967 Nov;202(9):882-8. [ Links ]

10. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 1963;118:99-120. [ Links ]

11. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 1;109(3):896-904. [ Links ]

12. Armijo JA, González M. Estudios de seguridad de medicamentos: métodos para detectar reacciones adversas y valoración de la relación causa - efecto. En: El ensayo Clínico en España. Madrid: Científica Farmaindustria;2001. p. 161-90. [ Links ]

13. Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS. Allergic Reactions and Anti-Asparaginase Antibodies in Children with High-Risk Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Cancer. 2015 Dec;121(23): 4205-11 [ Links ]

14. Cabral dos Santos A, Gerardin Poirot Land M,Peroni da Silva N,Oliveira Santos K, da Costa Lima-Dellamora E. Reactions related to asparaginase infusion in a 10-year retrospective cohort. Rev Bras Hematol Hemoter. 2017;3 9(4):337-42. [ Links ]

15. Henriksen LT, Harila-Saari A, Ruud E, Abrahamsson J, Pruunsild K, Vaitkeviciene G, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015 Mar;62(3):427-33. [ Links ]

16. Cuba en números: Lo que el Censo nos dejó. 16 abril 2014. [Citado 20/12/2017]. Disponible en: http://www.cubadebate.cu/noticias/2014/04/16/cuba-en-numeros-lo-que-el-censo-nos-dejo/#.W4UbgKMg61s. [ Links ]

17. Cernadas JR. Reactions to cytostatic agents in children. Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):255-61. [ Links ]

18. Alrazzak M, Beaupin LK, Kinyoun P, Barth M. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience. J Pediatr Hematol Oncol. 2016 Jan;38(1):e16-20. [ Links ]

19. Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddard K. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. Pediatr Blood Cancer. 2017 Jan;64(1):81-8. [ Links ]

20. Browne EK, Moore C, Sykes A, Lu Z, Jeha S, Mandrell BN. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia. J Pediatr Oncol Nurs. 2018 Mar/Apr;35(2):103-9. [ Links ]

21. Yen HJ, Chang WH, Liu HC, Yeh TC, Hung GY, Wu KH, et al. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Apr;63(4):665-70. [ Links ]